Vita Prof. Dr. med. Bjoern Andrew Remppis

• Kardio-renales Syndrom: Bauchfell-Dialyse
• Serologische Infarktdiagnostik: Entwicklung des Troponin-T-Tests als neuen Goldstandard der Infarktdiagnostik
• Molekulare Herzinsuffizienzforschung: Definition des Ca bindenden Proteins S100A1 als zentralen Regulator der myokardialen Kontraktilität und Entwicklung einer Gentherapie zur Behandlung der Herzinsuffizienz mit weltweitem Patent
• Klinische Herzinsuffizienzforschung: Aufbau des HELUMA Herzinsuffizienzregisters mit klinischer Versorgungsforschung, Entwicklung eines AOK IV-Vertrages mit inkludierter telemedizinischer Versorgung
• Vegetative Medizin: Integration klassischer chinesischer Medizinstrategien in westliche Konzepte der systemweiten Stresspathophysiologie
• Kardio-pulmo-renale Medizin: HFpEF als Modellerkrankung der kardio-pulmo-renalen Interaktionen, CpcPH und IpcPH als Determinanten eines besonderen HFpEF-Phänotyps

Versorgungsforschung

• Innovationsfonds Herz-Check / Konsortialpartner (Förderkennzeichen 01NVF19014): Mobiles Herz-MRT zur Detektion subklinischer Herzinsuffizienz - Mobiles Konzept für modernste Therapie im ländlichen Raum
• Innovationsfonds Precovery / Konsortialpartner (Förderkennzeichen 01NVF 21010): Prehabilitation „Karl Heinz“ mit Schwerpunkt auf kardiale und kognitive Funktion vor Eingriffen am Herzen - Eine Analyse des Gesundheitszustandes
• Innovationsfonds R2D - Ready to discharge? / Konsortialpartner (Förderkennzeichen VSF1_2022-064): Umsetzung, Einflussfaktoren und Effekte des Entlassmanagements in der kardiologischen Versorgung

Gentherapie der Herzinsuffizienz, experimentell

• Weber C, Neacsu I, Krautz B, Schlegel P, Sauer S, Raake P, Ritterhoff J, Jungmann A, Remppis AB, Stangassinger M, Koch WJ, Katus HA, Müller OJ, Most P, Pleger ST. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther. 2014 Feb;21(2):131-8.
• Kraus C, Rohde D, Weidenhammer C, Qiu G, Pleger ST, Voelkers M, Boerries M, Remppis A, Katus HA, Most P. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol. 2009 Oct;47(4):445-55.
• Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, Gao E, Dasgupta A, Rengo G, Remppis A, Katus HA, Eckhart AD, Rabinowitz JE, Koch WJ. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007 May 15;115(19):2506-15.
• Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R568-77
• Pleger ST, Most P, Heidt B, Voelkers M, Hata JA, Katus HA, Remppis A, Koch WJ. S100A1 gene transfer in myocardium. Eur J Med Res. 2006 Oct 27;11(10):418-22
• Pleger ST, Remppis A, Heidt B, Völkers M, Chuprun JK, Kuhn M, Zhou RH, Gao E, Szabo G, Weichenhan D, Müller OJ, Eckhart AD, Katus HA, Koch WJ, Most P. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction.Mol Ther. 2005 Dec;12(6):1120-9.
• Most P, Pleger ST, Völkers M, Heidt B, Boerries M, Weichenhan D, Löffler E, Janssen PM, Eckhart AD, Martini J, Williams ML, Katus HA, Remppis A, Koch WJ. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004 Dec;114(11):1550-63.
• Remppis A, Pleger ST, Most P, Lindenkamp J, Ehlermann P, Schweda C, Löffler E, Weichenhan D, Zimmermann W, Eschenhagen T, Koch WJ, Katus HA. S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med. 2004 Apr;6(4):387-94.
• Most P, Boerries M, Eicher C, Schweda C, Ehlermann P, Pleger ST, Loeffler E, Koch WJ, Katus HA, Schoenenberger CA, Remppis A. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem. 2003 Nov 28;278(48):48404-12.
• Most P, Remppis A, Pleger ST, Löffler E, Ehlermann P, Bernotat J, Kleuss C, Heierhorst J, Ruiz P, Witt H, Karczewski P, Mao L, Rockman HA, Duncan SJ, Katus HA, Koch WJ. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem. 2003 Sep 5;278(36):33809-17.
• Remppis A, Most P, Löffler E, Ehlermann P, Bernotat J, Pleger S, Börries M, Reppel M, Fischer J, Koch WJ, Smith G, Katus HA. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol. 2002;97 Suppl 1:I56-62.
• Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Börries M, Niroomand F, Pieske B, Janssen PM, Eschenhagen T, Karczewski P, Smith GL, Koch WJ, Katus HA, Remppis A. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13889-94
• Remppis A, Greten T, Schäfer BW, Hunziker P, Erne P, Katus HA, Heizmann CW. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta. 1996 Oct 11;1313(3):253-7.

Herzinsuffizienz, klinisch

• Müller D, Remppis A, Schauerte P, Schmidt-Schweda S, Burkhoff D, Rousso B, Gutterman D, Senges J, Hindricks G, Kuck KH. Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction. Clin Res Cardiol. 2017 Jul 6. doi: 10.1007/s00392-017-1135-9.
• Tschöpe C, Van Linthout S, Spillmann F, Klein O, Biewener S, Remppis A, Gutterman D, Linke WA, Pieske B, Hamdani N, Roser M. Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. Int J Cardiol. 2016 Jan 15;203:1061-6.
• Peters-Klimm F, Laux G, Campbell S, Müller-Tasch T, Lossnitzer N, Schultz JH, Remppis A, Jünger J, Nikendei C. Physician and patient predictors of evidence-based prescribing in heart failure: a multilevel study.PLoS One. 2012;7(2):e31082.
• Gupta RC, Mishra S, Rastogi S, Wang M, Rousso B, Mika Y, Remppis A, Sabbah HN. Ca(2+)-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals. Clin Transl Sci. 2009 Jun;2(3):211-5.
• Frankenstein L, Remppis A, Giannitis E, Frankenstein J, Hess G, Zdunek D, Doesch A, Zugck C, Katus HA. Biological variation of high sensitive Troponin T in stable heart failure patients with ischemic or dilated cardiomyopathy.Clin Res Cardiol. 2011 Aug;100(8):633-40.
• Frankenstein L, Zugck C, Nelles M, Schellberg D, Katus HA, Remppis BA. The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders.Eur J Heart Fail. 2009 Dec;11(12):1189-94.
• Frankenstein L, Zugck C, Schellberg D, Nelles M, Froehlich H, Katus H, Remppis A. Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure. Eur J Heart Fail. 2009 Feb;11(2):178-84.
• Peters-Klimm F, Müller-Tasch T, Remppis A, Szecsenyi J, Schellberg D. Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. J Eval Clin Pract. 2008 Oct;14(5):823-9
• Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, Misier AR, Curnis A, Böcker D, Remppis A, Kautzner J, Stühlinger M, Leclerq C, Táborsky M, Frigerio M, Parides M, Burkhoff D, Hindricks G. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure.Eur Heart J. 2008 Apr;29(8):1019-28.
• Koelsch S, Remppis A, Sammler D, Jentschke S, Mietchen D, Fritz T, Bonnemeier H, Siebel WA. A cardiac signature of emotionality. Eur J Neurosci. 2007 Dec;26(11):3328-38.
• Anker SD, Borggrefe M, Neuser H, Ohlow MA, Röger S, Goette A, Remppis BA, Kuck KH, Najarian KB, Gutterman DD, Rousso B, Burkhoff D, Eur J Heart Fail. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. 2019 Sep;21(9):1103-1113. doi: 10.1002/ejhf.1374. Epub 2019 Jan 16.

Kardiorenales Syndrom

• Schlieper G, Schwenger V, Remppis A, Keller T, Dechend R, Massberg S, Baldus S, Weinreich T, Hetzel G, Floege J, Mahfoud F, Fliser D. Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology. Internist (Berl). 2017 May;58(5):512-521.
• Schwenger V, Remppis BA, Westenfeld R, Weinreich T, Brunkhorst R, Schieren G, Krumme B, Haller H, Schmieder R, Schlieper G, Frye B, Hoppe UC, Hoyer J, Keller T, Blumenstein M, Schunkert H, Mahfoud F, Rump LC. Dialysis and ultrafiltration therapy in patients with cardio-renal syndrome: recommendations of the working group "heart-kidney" of the German Cardiac Society and the German Society of Nephrology. Dtsch Med Wochenschr. 2014 Feb;139(7):e1-8.
• Schwenger V, Remppis AB. Renal replacement therapy for refractory heart failure. Internist 2012 Jul;53(7):823-32.
• Remppis A, Ritz E. Cardiac problems in the dialysis patient: beyond coronary disease. Semin Dial. 2008 Jul-Aug;21(4):319-25.
• Fröhlich H, Katus HA, Täger T, Lossnitzer N, Grossekettler L, Kihm L, Zeier M, Remppis A, Frankenstein L, Schwenger V. Peritoneal ultrafiltration in end-stage chronic heart failure.Clin Kidney J. 2015 Apr;8(2):219-25.
• Haller C, Zehelein J, Remppis A, Müller-Bardorff M, Katus HA. Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. Clin Chem. 1998 May;44(5):930-8.
• Katus HA, Haller C, Müller-Bardorff M, Scheffold T, Remppis A. Cardiac troponin T in end-stage renal disease patients undergoing chronic maintenance hemodialysis. Clin Chem. 1995 Aug;41 (8 Pt 1):1201-3.
• Grossekettler L, Schmack B, Meyer K, Brockmann C, Wanninger R, Kreusser MM, Frankenstein L, Kihm LP, Zeier M, Katus HA, Remppis A, Schwenger V.Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail. 2019 Apr;6(2):271-279. doi: 10.1002/ehf2.12411. Epub 2019 Feb 27. PMID: 30815994 

Inflammation

• Volz HC, Seidel C, Laohachewin D, Kaya Z, Müller OJ, Pleger ST, Lasitschka F, Bianchi ME, Remppis A, Bierhaus A, Katus HA, Andrassy M. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol. 2010 Nov;105(6):805-20.
• Pleger ST, Harris DM, Shan C, Vinge LE, Chuprun JK, Berzins B, Pleger W, Druckman C, Völkers M, Heierhorst J, Øie E, Remppis A, Katus HA, Scalia R, Eckhart AD, Koch WJ, Most P. Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res. 2008 Apr 11;102(7):786-94
• Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbäurl H, Nawroth PP, Remppis A, Katus HA, Bierhaus A. High-mobility group box-1 in ischemia-reperfusion injury of the heart.Circulation. 2008 Jun 4; 117 (25): 3216-26.
• Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, Nawroth PP, Katus HA, Remppis A. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006 Mar 30;5:6.
• Koch A, Palchyk E, Gassler N, Dengler TJ, Remppis A, Pritsch M, Sack FU, Hagl S, Schnabel PA. Expression of platelet-derived growth factor and fibroblast growth factor in cryopreserved endomyocardial biopsies early and late after heart transplant. Ann Thorac Surg. 2006 Apr;81(4):1372-8.
• Ehlermann P, Mirau W, Jahn J, Remppis A, Sheikhzadeh A. Predictive value of inflammatory and hemostatic parameters, atherosclerotic risk factors, and chest x-ray for aortic arch atheromatosis. Stroke. 2004 Jan;35(1):34-9
• Pauschinger M, Doerner A, Remppis A, Tannhäuser R, Kühl U, Schultheiss HP. Differential myocardial abundance of collagen type I and type III mRNA in dilated cardiomyopathy: effects of myocardial inflammation. Cardiovasc Res. 1998 Jan;37(1):123-9.
• Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ 3rd, Schäfer BW. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13164-9.

Kardiales Troponin-T: Etablierung eines neuen Infarktmarkers

• Frankenstein L, Remppis A, Giannitis E, Frankenstein J, Hess G, Zdunek D, Doesch A, Zugck C, Katus HA. Biological variation of high sensitive Troponin T in stable heart failure patients with ischemic or dilated cardiomyopathy. Clin Res Cardiol. 2011 Aug;100(8):633-40
• Remppis A, Ehlermann P, Giannitsis E, Greten T, Most P, Müller-Bardorff M, Katus HA. Cardiac troponin T levels at 96 hours reflect myocardial infarct size: a pathoanatomical study.Cardiology. 2000;93(4):249-53
• Müller-Bardorff M, Rauscher T, Kampmann M, Schoolmann S, Laufenberg F, Mangold D, Zerback R, Remppis A, Katus HA. Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. Clin Chem. 1999 Jul;45(7):1002-8.
• Müller-Bardorff M, Hallermayer K, Schröder A, Ebert C, Borgya A, Gerhardt W, Remppis A, Zehelein J, Katus HA. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem. 1997 Mar;43(3):458-66.
• Müller-Bardorff M, Freitag H, Scheffold T, Remppis A, Kübler W, Katus HA. Development and characterization of a rapid assay for bedside determinations of cardiac troponin T. Circulation. 1995 Nov 15;92(10):2869-75.
• Remppis A, Scheffold T, Greten J, Haass M, Greten T, Kübler W, Katus HA. Intracellular compartmentation of troponin T: release kinetics after global ischemia and calcium paradox in the isolated perfused rat heart. J Mol Cell Cardiol. 1995 Feb;27(2):793-803.
• Remppis A, Scheffold T, Karrer O, Zehelein J, Hamm C, Grünig E, Bode C, Kübler W, Katus HA. Assessment of reperfusion of the infarct zone after acute myocardial infarction by serial cardiac troponin T measurements in serum. Br Heart J. 1994 Mar;71(3):242-8.
• Katus HA, Looser S, Hallermayer K, Remppis A, Scheffold T, Borgya A, Essig U, Geuss U. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem. 1992 Mar;38(3):386-93.
• Katus HA, Remppis A, Scheffold T, Diederich KW, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol. 1991 Jun 15;67(16):1360-7.
• Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, Noe A, Matern G, Kuebler W. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation. 1991 Mar;83(3):902-12.
• Katus HA, Remppis A, Looser S, Hallermeier K, Scheffold T, Kübler W. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol. 1989 Dec;21(12):1349-53.

Traditionelle Chinesische Medizin

• von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Edler L, Munzinger J, Efferth T, Schneeweiss A, Strowitzki T. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast Cancer Res Treat. 2017 Jul;164(2):359-369.
• Maimer A, Remppis A, Sack FU, Ringes-Lichtenberg S, Greten T, Brazkiewicz F, Schröder S, Goncalves M, Efferth T, Greten HJ. Objectifying acupuncture effects by lung function and numeric rating scale in patients undergoing heart surgery. Evid Based Complement Alternat Med. 2013;2013:219817.
• Karner M, Brazkiewicz F, Remppis A, Fischer J, Gerlach O, Stremmel W, Subramanian SV, Greten HJ. Objectifying specific and nonspecific effects of acupuncture: a double-blinded randomised trial in osteoarthritis of the knee.Evid Based Complement Alternat Med. 2013;2013:427265.
• Remppis A, Bea F, Greten HJ, Buttler A, Wang H, Zhou Q, Preusch MR, Enk R, Ehehalt R, Katus H, Blessing E. Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010;2010:194896.
• Kelemen K, Kiesecker C, Zitron E, Bauer A, Scholz E, Bloehs R, Thomas D, Greten J, Remppis A, Schoels W, Katus HA, Karle CA. Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels. Biochem Biophys Res Commun. 2007 Dec 21;364(3):429-35.
• Schröder S, Liepert J, Remppis A, Greten JH. Acupuncture treatment improves nerve conduction in peripheral neuropathy. Eur J Neurol. 2007 Mar;14(3):276-81.
• Enk R, Ehehalt R, Graham JE, Bierhaus A, Remppis A, Greten HJ. Differential effect of Rhizoma coptidis and its main alkaloid compound berberine on TNF-alpha induced NFkappaB translocation in human keratinocytes. J Ethnopharmacol. 2007 Jan 3;109(1):170-5
• Scholz EP, Zitron E, Kiesecker C, Thomas D, Kathöfer S, Kreuzer J, Bauer A, Katus HA, Remppis A, Karle CA, Greten J. Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656. Nutr Metab Cardiovasc Dis. 2007 Nov;17(9):666-75.

Dissertationsschrift
Nachweis von Isoformen myofibrillären Troponin-T's: Mögliche klinische Bedeutung (1990, Universität Heidelberg)

Habilitationsschrift
Das cardiale Ca²⁺ bindende Protein S100A2: Funktionelle Charakterisierung und klinische Bedeutung (2001, Universität Lübeck)    

Patente  

• Treatment of cardiac power failure, US 7588756 B1
• Muscle function enhancing peptide , US 9428564 B2
• Muscle function enhancing peptide, WO 2010118878 A1
• Treatment of cardiac power failure using s100 proteins, WO 2000061742 A2
• Peptid zur Verbesserung der Muskelfunktion, EP 2419119 B1
• Short peptides for enhancing muscle function, CA 2814967 A1
• Therapie der Herzinsuffizienz, DE 19915485 A1
• Enhance muscle function peptides, CN 102395377 B (增强肌肉功能的肽 )